Energenesis Biomedical Co. Ltd.
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel … Read more
Energenesis Biomedical Co. Ltd. (6657) - Net Assets
Latest net assets as of September 2025: NT$993.95 Million TWD
Based on the latest financial reports, Energenesis Biomedical Co. Ltd. (6657) has net assets worth NT$993.95 Million TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.03 Billion) and total liabilities (NT$37.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$993.95 Million |
| % of Total Assets | 96.33% |
| Annual Growth Rate | -1.23% |
| 5-Year Change | 9.87% |
| 10-Year Change | N/A |
| Growth Volatility | 24.28 |
Energenesis Biomedical Co. Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how Energenesis Biomedical Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Energenesis Biomedical Co. Ltd. (2019–2024)
The table below shows the annual net assets of Energenesis Biomedical Co. Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$739.33 Million | -8.04% |
| 2023-12-31 | NT$803.98 Million | +33.43% |
| 2022-12-31 | NT$602.56 Million | -29.31% |
| 2021-12-31 | NT$852.38 Million | +26.67% |
| 2020-12-31 | NT$672.92 Million | -14.44% |
| 2019-12-31 | NT$786.49 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Energenesis Biomedical Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3131100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$905.70 Million | 122.50% |
| Other Components | NT$64.71 Million | 8.75% |
| Total Equity | NT$739.33 Million | 100.00% |
Energenesis Biomedical Co. Ltd. Competitors by Market Cap
The table below lists competitors of Energenesis Biomedical Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Integrated Wind Solutions AS
OL:IWS
|
$98.92 Million |
|
Shanthi Gears Limited
NSE:SHANTIGEAR
|
$98.94 Million |
|
New Power Plasma Co.Ltd
KQ:144960
|
$98.94 Million |
|
PT Harum Energy Tbk
F:44H
|
$98.95 Million |
|
SCHMID Group N.V. Class A Ordinary Shares
NASDAQ:SHMD
|
$98.90 Million |
|
LuxExperience B.V.
NYSE:LUXE
|
$98.88 Million |
|
Kee Tai Properties Co Ltd
TW:2538
|
$98.87 Million |
|
Uniplus Electronics Co Ltd
TWO:5381
|
$98.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Energenesis Biomedical Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 803,983,000 to 739,333,000, a change of -64,650,000 (-8.0%).
- Net loss of 231,080,000 reduced equity.
- New share issuances of 151,486,000 increased equity.
- Other comprehensive income decreased equity by 501,999.
- Other factors increased equity by 15,445,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-231.08 Million | -31.26% |
| Share Issuances | NT$151.49 Million | +20.49% |
| Other Comprehensive Income | NT$-502.00K | -0.07% |
| Other Changes | NT$15.45 Million | +2.09% |
| Total Change | NT$- | -8.04% |
Book Value vs Market Value Analysis
This analysis compares Energenesis Biomedical Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.97x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.22x to 4.97x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$14.91 | NT$47.95 | x |
| 2020-12-31 | NT$11.39 | NT$47.95 | x |
| 2021-12-31 | NT$14.19 | NT$47.95 | x |
| 2022-12-31 | NT$9.04 | NT$47.95 | x |
| 2023-12-31 | NT$11.18 | NT$47.95 | x |
| 2024-12-31 | NT$9.65 | NT$47.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Energenesis Biomedical Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -31.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2982.06%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.06x
- Recent ROE (-31.26%) is below the historical average (-26.69%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -19.04% | -2395.98% | 0.01x | 1.03x | NT$-228.42 Million |
| 2020 | -19.24% | -1828.54% | 0.01x | 1.05x | NT$-196.77 Million |
| 2021 | -14.11% | -1605.50% | 0.01x | 1.04x | NT$-205.47 Million |
| 2022 | -44.09% | -3613.98% | 0.01x | 1.05x | NT$-325.92 Million |
| 2023 | -32.39% | -3637.64% | 0.01x | 1.03x | NT$-340.78 Million |
| 2024 | -31.26% | -2982.06% | 0.01x | 1.06x | NT$-305.01 Million |
Industry Comparison
This section compares Energenesis Biomedical Co. Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Energenesis Biomedical Co. Ltd. (6657) | NT$993.95 Million | -19.04% | 0.04x | $98.92 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |